LifePort Liver Transporter has not been cleared or approved by FDA, and the safety and effectiveness of the LifePort Liver Transporter has not been established. LifePort Liver Transporter is not available for sale within the United States.

A recent review article by Amin et al. focused on the mechanistic actions of hypothermic machine perfusion (HMP) in liver graft preservation, the clinical literature of HMP in liver transplantation and the future directions of clinical application of HMP in liver transplantation.

They highlighted the following key points:

• Due to its ability to provide oxygen and nutrients and remove toxic metabolic waste products, HMP leads to less severe ischemic reperfusion injury
• Current clinical evidence has shown that HMP provides decreased biliary complications and lower early allograft dysfunction (EAD) rates which leads to increased liver graft survival
• Recent studies looking at viability assessment during HMP show promising results, such as those analyzing flavin mononucleotide (FMN)

Overall, they concluded that HMP for liver graft preservation has the potential to increase the number of liver transplants and improve results with livers from donors after circulatory death (DCD) and extended criteria donors after brain death (DBD).

Read the full article here: https://journals.lww.com/co-transplantation/Citation/2022/04000/Hypothermic_machine_perfusion_for_liver_graft.3.aspx